Elk Creek Partners’s Heron Therapeutics HRTX Stock Holding History

Elk Creek Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$5.98M	Buy	509,174 +46,600	+10%	+$876K	1.03%	36
2019 Q4	$10.9M	Sell	462,574 -163,062	-26%	-$3.61M	1.25%	27
2019 Q3	$11.6M	Sell	625,636 -42,604	-6%	-$784K	1%	40
2019 Q2	$12.4M	Buy	+668,240	New	+$13.3M	0.93%	39

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Elk Creek Partners's HRTX Position: Q1 2020 in Review

Elk Creek Partners increased its Heron Therapeutics (HRTX) stake by 10% in Q1 2020, buying an estimated $876K and bringing the position to 509,174 shares worth $5.98M. The position accounts for 1.03% of the portfolio, ranked #36.

Elk Creek Partners first reported a position in HRTX in Q2 2019 and has held it in 4 quarters since. The position peaked at $12.4M in Q2 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Elk Creek Partners held 509,174 shares of Heron Therapeutics worth $5.98M as of Q1 2020.
Elk Creek Partners bought 46,600 Heron Therapeutics shares in Q1 2020, an estimated $876K.
Heron Therapeutics made up 1.03% of Elk Creek Partners's portfolio in Q1 2020, its #36 holding.
Elk Creek Partners first reported a position in Heron Therapeutics in Q2 2019 and has held it in 4 quarters since.
Elk Creek Partners's Heron Therapeutics position peaked at $12.4M in Q2 2019.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.